CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
Living with CLL
Activity and Exercise Likely Improve Quality of Life in CLL
People with CLL benefit from exercise, likely improving quality of life, yet they are rarely “prescribed” it and are less active than their peers.
My CLL Immunity is Impaired in Both My B and T Cells
Infections are the leading cause of death in chronic lymphocytic leukemia (CLL). My epcoritamab trial has put me at risk.
Doing Great Two Years on My Epcoritamab Trial: Time to Stop?
August 2025 marks 2 years on the epcoritamab trial for Dr. Koffman. Since February 2024, blood tests have shown 0-1 cancer cell per million blood cells. Time to quit?
Sharing the CLL Experience: The Role of Reflection and Support
Dr. Ratner offers his memories through the lens of a physician with CLL who specializes in the care of older adults and as a Support Group facilitator.
Cancer, CLL, and Mindfulness
When diagnosed with chronic lymphocytic leukemia (CLL), doctors should pause and help patients understand the watch and wait period.
Dr. Ratner offers his memories through the lens of a physician with CLL who specializes in the care of older adults and as a Support Group facilitator.
WHAT'S NEW IN CLL / SLL
Ambassador Program for Chronic Lymphocytic Leukemia (CLL) Patients
For those living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL), there are a number of treatment options to choose from. When it comes to time to treat, peer-to-peer dialogue can be a highly valuable form of learning and reminds us that we are not alone in this journey.
If you are living with CLL / SLL and considering various treatment options, CLL Society’s Ambassador Program can connect you with a fellow CLL patient who has received the treatment.
ADVOCACY AND POLICY
CLL Society Urges Centers for Medicare and Medicaid Services to Carefully Consider the Nature of CLL in Evaluating Treatments for NTAP
CLL Society is actively monitoring changes in the federal government agencies that may affect federal employees’ ability to continue serving patients.
CLL Society Opposes Proposed Changes to ACA Plan Processes Likely to Disrupt Enrollment and Coverage
CLL Society Opposes Proposed Changes to ACA Plan Processes Likely to Disrupt Enrollment and Coverage
CLL Society Joins Growing Number of Groups Calling for Patient Protections from Medicare Part D Plan Utilization Management Under New IRA Kickoff
CLL Society joins 70+ groups urging CMS to protect CLL patients from Medicare Part D delays in medication access.
UPCOMING EVENTS
Thursday, September 18, 2025 at 9:30 AM PT / 12:30 PM ET
Join CLL Society for our webinar Understanding Medicare and CLL: What Patients Need to Know, designed to help individuals living with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) better understand how Medicare works and what it means for their care. This session will cover the basics of Medicare, how different parts of the program apply to CLL treatment, and what patients should consider when choosing a plan. We’ll also discuss the difference between “traditional” Medicare and Medicare Advantage, common coverage challenges, out-of-pocket costs, and recent updates that may impact access to medications and services. Whether you’re new to Medicare or looking to better navigate your current coverage, this webinar will provide practical guidance to help you make more informed decisions about your care.
On-Demand Replay
If you missed the recent webinar with Jennifer R. Brown, MD, PhD and Terry Evans on Next-Generation CLL Treatments: Understanding Clinical Trials and Future Therapeutic Strategies, catch the replay, presentation slides, and transcript here! Watch now!
If you missed the recent Q&A-style Facebook Live event “Ask Me Anything” with Dr. Lindsey Roeker and patient advocate Jeff Folloder, you can catch the replay here!
Treatment Updates
Richter Transformation in the Era of Targeted Therapies
Outcomes for patients with Richter transformation remain poor even with the introduction of targeted therapies.
Zanubrutinib and Venetoclax for Relapsed / Refractory CLL
An ongoing phase 2 clinical trial is evaluating the efficacy and tolerability of fixed-duration zanubrutinib plus venetoclax for relapsed / refractory CLL.
Real-World Prevalence of BTK Mutations in Patients with CLL
In patients being treated with BTK inhibitors, mutations in BTK are relatively rare (2 in 100 patients).
Equitable Access and Regulatory News
FDA Drops REMS, a Plan to Reduce Risk for CAR-T in CLL
The FDA’s mandatory plans to manage drug risks or REMS (Risk Evaluation and Mitigation Strategies) were dropped for CAR-T, making it more accessible in CLL.
EU Approves Acalabrutinib-Based Combinations for CLL
The EU commission has approved acalabrutinib in combination with venetoclax, with or without obinutuzumab, for the frontline treatment of CLL.
Understanding NCCN Guidelines for CLL / SLL as a Patient
NCCN guidelines are the gold standard where CLL experts recommend best practices. Learn what CLL patients should know about the latest update.